|
|
Home > Healthcare > Pharmaceutical > General Pharmaceutical
Zimbabwe Pharmaceuticals and Healthcare Report Q3 2009
|
|
- Executive Summary
- SWOT Analysis
- Zimbabwe Pharmaceuticals And Healthcare Industry SWOT
- Zimbabwe Political SWOT
- Zimbabwe Economic SWOT
- Zimbabwe Business Environment SWOT
- Pharmaceutical Business Environment Ratings
- Table: Middle East and Africa (MEA) - Regional Pharma Business Environment Ratings For Q309
- Limits of Potential Returns
- Risks to Realisation of Returns
- Zimbabwe - Market Summary
- Regulatory Regime
- Intellectual Property Developments
- Pricing and Reimbursement Issues
- Public Drug Procurement
- Industry Developments
- Epidemiology
- Communicable Diseases
- Cholera Crisis
- HIV/AIDS Situation
- Healthcare System
- Healthcare Funding
- Recent Healthcare System Developments
- Healthcare Staff
- Pharmaceutical Sector
- Recent Pharmaceutical Sector Developments
- Table: ARV Prices Available Through Direct Purchase From Roche (CHF)
- Pharmacy Sector
- Traditional Medicine
- Biotechnology Sector Developments
- Medical Devices
- Industry Forecast Scenario
- Overall Market Forecasts
- Table: Zimbabwe - Drug Market Forecast, Historical Data and Forecasts
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: Zimbabwe - Economic Activity
- Prescription Drug Market Forecast
- Table: Zimbabwe - Prescription Drug Market Indicators, Historical Data and Forecasts (US$mn unless otherwise indicated)
- Patented Drug Market Forecast
- Table: Zimbabwe - Patented Market Forecast, Historical Data and Forecasts
- Generic Drug Market Forecast
- Table: Zimbabwe - Generic Drug Market Indicators*, Historical Data and Forecasts
- OTC Drug Market Forecast
- Table: Zimbabwe - OTC Drug Market Forecast, Historical Data and Forecasts (US$mn unless otherwise indicated)
- Pharmaceutical Trade Forecasts
- Table: Zimbabwe - Pharmaceutical Trade Balance, Historical Data and Forecasts (US$mn)
- Other Healthcare Data Forecasts
- Table: Zimbabwe - Other Healthcare Forecasts, Historical Data and Forecasts
- Key Risks to BMI Forecasts
- Competitive Landscape
- Company Profiles
- Multinational Companies
- Ranbaxy
- Pfizer
- Novartis
- Sanofi-Aventis
- Merck & Co
- GlaxoSmithKline
- Indigenous Companies
- Datlabs
- Varichem Laboratories
- CAPS Holdings
- Country Snapshot: Zimbabwe Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education and Healthcare
- Table: Education, 2000-2003
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market and Spending Power
- Table: Employment Indicators, 1997 And 1999*
- Table: Average Annual Manufacturing Wages, 1996-2002
- BMI Forecast Modelling
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
|
Similar Products
• United States Type 2 Diabetes Market
Published Nov 2009 by Intellent
• Snapshots Poland Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots Venezuela Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots Spain Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots South Africa Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots Hungary Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Nigeria Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Kenya Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Company Financials: Bayer AG
Published Nov 2009 by Datamonitor
• Merck & Co. Performance, Products, Pipeline and Potential
Published Nov 2009 by Espicom Healthcare Intelligence
|
|
|
|
0 items
